Yttrium Y 90 Basiliximab

BIOLOGICAL3 trials

Sponsors

City of Hope Medical Center

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMyelodysplastic SyndromeRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRefractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Phase 1

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

CompletedNCT02342782

City of Hope Medical CenterMature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma +2

Start: 2020-06-08End: 2024-11-18Updated: 2025-03-20

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Active, not recruitingNCT05139004

City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome +1

Start: 2022-07-19End: 2027-06-13Updated: 2025-07-08

Phase 2

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

RecruitingNCT04871607

City of Hope Medical CenterRecurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma

Start: 2021-11-02End: 2029-10-02Target: 33Updated: 2025-12-04

Related Papers

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood2025-11-03

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma

Blood Advances2024-06-051 citations

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

Blood Advances2021-10-1713 citations